temozolomide has been researched along with zk-219477 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fichtner, I; Hess-Stumpp, H; Hoffmann, J; Hofmann, B; Klar, U; Lemm, M; Lienau, P; Rotgeri, A | 1 |
1 other study(ies) available for temozolomide and zk-219477
| Article | Year |
|---|---|
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Benzothiazoles; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epothilones; Female; Half-Life; Humans; Male; Mice; Mice, Nude; Paclitaxel; Rats; Rats, Wistar; Survival Rate; Temozolomide; Xenograft Model Antitumor Assays | 2009 |